1 Broadway, 14th floor
11 articles with Checkmate Pharmaceuticals
What if you could more precisely control CAR-T cells using FDA-approved small molecules to enhance their activity against solid tumors? That’s exactly what Obsidian Therapeutics is aiming to do.
Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat advanced cancer, announced the addition of Alan Fuhrman to its Board of Directors.
Checkmate Pharmaceuticals Announces Appointment of Keith T. Flaherty, M.D. to its Board of Directors
Checkmate Pharmaceuticals Inc. announced the addition of Keith T. Flaherty, M.D. to its Board of Directors.
Checkmate Pharmaceuticals, a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat advanced cancer, has appointed Barry Labinger as President and CEO. Arthur M. Krieg, MD, Checkmate’s founder and current President and CEO, will assume the newly-created role of Chief Scientific Officer.
Checkmate Pharmaceuticals Announces Start of Phase 1b Trial of CMP-001 in Combination with Anti-PD-L1 Immunotherapy in Anti-PD-1/PD-L1 Resistant Advanced Non-Small Cell Lung Cancer
CMP-001 Clinical Studies Expand into Second Tumor Type
The following is a roundup of presentations and findings from multiple companies participating in the 2018 American Association for Cancer Research (AACR) in Chicago.
Checkmate Appoints David Mauro, M.D., Ph.D., As Chief Medical Officer And Announces Dosing Of First Patient In Immuno-Oncology Phase 1b Trial With CMP-001, A TLR9 Agonist
BioSpace is pleased to present its NextGen Bio “Class of 2016.” This list contains 20 life science companies that launched no earlier than 2013 and are headquartered in the United States.